K. Shitara Et Al. , "Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma," ANNALS OF ONCOLOGY , vol.32, no.9, pp.1127-1136, 2021
Shitara, K. Et Al. 2021. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. ANNALS OF ONCOLOGY , vol.32, no.9 , 1127-1136.
Shitara, K., ÖZGÜROĞLU, M., Bang, Y., Di Bartolomeo, M., Mandala, M., Ryu, M., ... Caglevic, C.(2021). Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. ANNALS OF ONCOLOGY , vol.32, no.9, 1127-1136.
Shitara, K. Et Al. "Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma," ANNALS OF ONCOLOGY , vol.32, no.9, 1127-1136, 2021
Shitara, K. Et Al. "Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma." ANNALS OF ONCOLOGY , vol.32, no.9, pp.1127-1136, 2021
Shitara, K. Et Al. (2021) . "Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma." ANNALS OF ONCOLOGY , vol.32, no.9, pp.1127-1136.
@article{article, author={K. Shitara Et Al. }, title={Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma}, journal={ANNALS OF ONCOLOGY}, year=2021, pages={1127-1136} }